CN110772607A - Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof - Google Patents
Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof Download PDFInfo
- Publication number
- CN110772607A CN110772607A CN201910997919.5A CN201910997919A CN110772607A CN 110772607 A CN110772607 A CN 110772607A CN 201910997919 A CN201910997919 A CN 201910997919A CN 110772607 A CN110772607 A CN 110772607A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- diabetic nephropathy
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for improving diabetic nephropathy, which comprises the following raw material medicines in parts by weight: 25-35 parts of astragalus membranaceus, 10-20 parts of eucommia ulmoides, 25-35 parts of corn stigma, 5-15 parts of coptis chinensis, 25-35 parts of salvia miltiorrhiza, and polygonum aviculare, flatstem milkvetch seed and oriental wormwood, wherein the polygonum aviculare is 15-25 parts, the flatstem milkvetch seed is 15-25 parts, and the oriental wormwood is 25-35 parts. The traditional Chinese medicine composition for improving the diabetic nephropathy can be used for treating the disease target of the diabetic nephropathy according to the modern system pharmacology theory; meanwhile, the traditional Chinese medicine composition conforms to the traditional Chinese medicine syndrome differentiation theoretical system, can effectively aim at the pathological characteristics of diabetic nephropathy by combining the medicines, has the advantages of less medicinal taste, reliable curative effect determination and definite main medicinal property components compared with other existing compound traditional Chinese medicines, can reduce non-medicinal effect factors in a traditional Chinese medicine compound preparation, and improves the preparation level.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving diabetic nephropathy and a preparation thereof.
Background
Diabetic nephropathy is a major microvascular complication of diabetes, mainly diabetic glomerulosclerosis, and is a glomerulopathy mainly caused by vascular damage. The early stage of the disease is asymptomatic, and continuous proteinuria, edema, hypertension, glomerular filtration rate reduction and the like appear along with the prolongation of the disease course, so that renal insufficiency and uremia are caused, and the diabetes is one of the main death reasons.
In recent years, the medicine treatment of the diabetic nephropathy is greatly improved, a systematic treatment scheme is provided clinically, the morbidity and the mortality cannot be reduced ideally, and the large-scale clinical application of the medicine in the treatment of the diabetic nephropathy is limited due to the side effect of western medicines and relatively high treatment cost, so that the long-term clinical treatment is difficult to complete. Therefore, the seeking of a treatment method and a medicine with definite clinical curative effect and small safety and toxic and side effects are always concerned by clinical workers in various countries, so that people turn to a treatment method of traditional Chinese medicine, namely traditional Chinese medicine.
The traditional Chinese medicine of China has no record of the disease name of diabetic nephropathy, modern Chinese medical researchers classify the disease name of the diabetic nephropathy into edema, turbid urine, diabetes, guan ge, kidney disease and the like according to the clinical manifestations of hypertension, and have no unified record of the disease name. According to the traditional Chinese medicine dialectical theory and epidemiological investigation and research, the diabetic nephropathy belongs to the deficiency of the origin and the excess of the origin, takes the deficiency of both the spleen and the kidney as the origin, and combines the excess syndromes of turbid toxin, water dampness, blood stasis and the like, so that the diabetes nephropathy needs to be treated by corresponding medicines for tonifying spleen and kidney, detoxifying and inducing diuresis, and activating blood and dissolving stasis. Therefore, the compound traditional Chinese medicine with definite curative effect is searched by combining modern pharmacology and traditional Chinese medicine syndrome differentiation system, and the compound traditional Chinese medicine has important significance for the traditional Chinese medicine treatment of the diabetic nephropathy.
Disclosure of Invention
The invention aims at providing a traditional Chinese medicine composition for improving diabetic nephropathy.
The second aspect of the invention aims to provide a traditional Chinese medicine preparation comprising the traditional Chinese medicine composition.
The third aspect of the invention aims to provide a preparation method of the traditional Chinese medicine preparation.
The technical scheme adopted by the invention is as follows:
the invention provides a traditional Chinese medicine composition for improving diabetic nephropathy, which comprises the following raw material medicines in parts by weight: 25-35 parts of astragalus membranaceus, 10-20 parts of eucommia ulmoides, 25-35 parts of corn stigma, 5-15 parts of coptis chinensis and 25-35 parts of salvia miltiorrhiza.
The traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 28-32 parts of astragalus membranaceus, 12-18 parts of eucommia ulmoides, 28-32 parts of corn stigma, 8-12 parts of coptis chinensis and 28-32 parts of salvia miltiorrhiza.
The traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 30 parts of astragalus membranaceus, 15 parts of eucommia ulmoides, 30 parts of corn stigma, 10 parts of coptis chinensis and 20 parts of salvia miltiorrhiza.
The traditional Chinese medicine composition further comprises polygonum aviculare, flatstem milkvetch seed and oriental wormwood, wherein 15-25 parts of polygonum aviculare, 15-25 parts of flatstem milkvetch seed and 25-35 parts of oriental wormwood.
The traditional Chinese medicine composition comprises 18-22 parts of polygonum aviculare, 18-23 parts of flatstem milkvetch seed and 28-32 parts of oriental wormwood.
According to the first aspect of the present invention, the traditional Chinese medicine composition comprises 20 parts of polygonum aviculare, 20 parts of semen astragali complanati and 30 parts of oriental wormwood.
The second aspect of the invention provides a traditional Chinese medicine preparation for treating diabetic nephropathy, which consists of the traditional Chinese medicine composition of the first aspect of the invention and pharmaceutically acceptable auxiliary materials.
According to the second aspect of the present invention, the active ingredient of the Chinese medicinal preparation is an aqueous extract.
In a third aspect of the present invention, there is provided a method for preparing the Chinese medicinal preparation according to the second aspect of the present invention, comprising the steps of:
s1, weighing raw material medicaments in proportion and crushing;
s2, placing the raw material medicaments crushed in the step S1 into a container, adding 50% methanol aqueous solution with the volume 6-12 times that of the raw material medicaments, heating, refluxing and cooling to obtain a mixed solution;
s3, placing the mixed liquor obtained in the step S2 in an ultrasonic water bath device, carrying out ultrasonic treatment for 60min, and cooling;
s4, centrifuging, taking the ultrasonic supernatant in the step S3, and filtering to obtain an aqueous extract.
According to the production method of the second aspect of the invention,
the ultrasonic processing conditions in step S3 are: the ultrasonic power is 600W, the frequency is 40KHz, and the temperature is 50 ℃;
and step S4, centrifuging for 15min under the centrifugation condition of 3000 r/min.
The pharmacology of the raw material medicaments of the invention is as follows:
coptis chinensis: is dried root of Astragalus membranaceus Bge Astragalus membrane aceus (Fisch.) of Leguminosae family or Astragalus membranaceus Bge. Hsiao (Bge.) or Astragalus membranaceus Bge. Astragalus membrane aceus (Fisch.) of Leguminosae family; sweet in flavor and slightly warm in nature; enters spleen and lung channels, and has the effects of invigorating spleen and replenishing qi, consolidating exterior, promoting diuresis, suppurating sepsis and promoting granulation.
Eucommia ulmoides: is dried bark of Eucommia ulmoides Oliv. of Eucommiaceae; sweet and slightly pungent in flavor and warm in nature; enter liver and kidney meridians, and have effects of nourishing liver and kidney, strengthening tendons and bones, preventing miscarriage, and lowering blood pressure.
Corn silk: the flower column and flower head of Zea mays L. of Zea of Gramineae; sweet, bland and mild in flavor. It enters bladder, liver and gallbladder meridians, and has the effects of inducing diuresis to alleviate edema, calming liver and promoting bile flow.
Coptis chinensis: dried rhizome of Coptis chinensis Franch, Coptis deltoidea C.Y.Cheng et Hsiao or Coptis Teeta wall of Ranunculaceae; bitter taste and cold nature. It enters heart, spleen, stomach, liver, gallbladder and large intestine meridians. Has the effects of clearing heat, eliminating dampness, purging pathogenic fire and removing toxic substances.
Red sage root: is dried root and rhizome of Salvia Miltiorrhiza bge of Labiatae; bitter taste and slightly cold nature, and has the effects of blood stasis dispelling, meridian passage dredging, pain relieving, heart fire clearing, vexation relieving, blood cooling and carbuncle eliminating.
Herba polygoni avicularis: is dried aerial parts of Polygonum aviculare L. of Polygonum aviculare of Polygonaceae; bitter taste and cold nature; entering bladder meridian, has effects of clearing heat, promoting urination, and killing parasite.
Flatstem milkvetch seed: is seed of Leguminosae plant Astragalus membranaceus bgelial R.Br; sweet taste and warm nature; entering liver and kidney meridians, has effects of warming and invigorating liver and kidney, arresting seminal emission, reducing urination, and improving eyesight.
Herba artemisiae scopariae: is dried aerial parts of Artemisia scoparia Waldst. et kit or Artemisia capillaris Artemisia apiacea Thunb. with bitter and pungent taste and slightly cold property; entering liver, gallbladder and spleen meridians, it has the effects of clearing away damp-heat and eliminating jaundice.
The invention has the beneficial effects that:
(1) the traditional Chinese medicine composition of the invention conforms to the theory of modern systemic pharmacology, and the selected medicine can be used as a disease target of diabetic nephropathy; simultaneously, the traditional Chinese medicine composition also conforms to the traditional Chinese medicine syndrome differentiation theoretical system, wherein the astragalus and the eucommia are used together to invigorate the spleen and tonify the kidney, the corn stigma and the coptis are used for detoxifying, promoting diuresis and removing turbidity, and the salvia is used for activating blood and dissolving stasis, and the combination of the medicines can effectively aim at the pathological characteristics of diabetic nephropathy;
(2) the traditional Chinese medicine composition has a definite effect of treating diabetic nephropathy: the in vivo experiment result shows that the traditional Chinese medicine composition can effectively reduce the blood sugar value of a diabetic nephropathy model rat, can improve the liver function index of the diabetic nephropathy model rat, and has the treatment effect in a dose-dependent relationship;
(3) compared with other existing compound traditional Chinese medicines, the components of the traditional Chinese medicine composition have the advantages of less medicinal ingredients, definite and reliable curative effect and definite main medicinal property components, can reduce non-medicinal effect factors in a traditional Chinese medicine compound preparation, and improve the preparation level.
Drawings
FIG. 1 is a network diagram of "drug-molecule-target-disease" of 499 Chinese herbs in TCMSP database;
FIG. 2 is a diagram of a "drug-molecule-target" network for diabetic nephropathy;
FIG. 3 shows the effect of the Chinese medicinal composition on blood glucose of rats in each group. (
*Represents P<0.05vs.DN，
**Represents P<0.01vs.DN，
***Represents P<0.001vs.DN)。
FIG. 4 shows the effect of the Chinese medicinal composition on the serum creatinine content of rats in each group. (
*Represents P<0.05vs.DN，
**Represents P<0.01vs.DN，
***Represents P<0.001vs.DN)。
FIG. 5 the effect of the Chinese medicinal composition on the urea nitrogen content of rats in each group. (
*Represents P<0.05vs.DN，
**Represents P<0.01vs.DN，
***Represents P<0.001vs.DN)。
Detailed Description
The invention is further illustrated by the following specific examples. The following examples are for illustrative purposes only and are not to be construed as limiting the invention. Unless otherwise specified, the raw materials used in the following examples, raw materials for reagents, were raw materials conventionally commercially available or commercially available. The apparatus used in the following examples is an apparatus conventionally used in the art unless otherwise specified.
Example 1
The traditional Chinese medicine preparation for improving diabetic nephropathy is prepared according to the following method, and comprises the following steps:
s1, weighing raw material medicaments comprising 25-35 parts of astragalus membranaceus, 30 parts of astragalus membranaceus, 15 parts of eucommia ulmoides, 30 parts of corn stigma, 10 parts of coptis chinensis, 20 parts of salvia miltiorrhiza, __ parts of polygonum aviculare, __ parts of flatstem milkvetch seeds and __ parts of oriental wormwood according to a proportion, and crushing;
s2, placing the raw material medicaments crushed in the step S1 into a container, adding 50% methanol aqueous solution with the volume 6-12 times that of the raw material medicaments, heating, refluxing and cooling to obtain a mixed solution;
s3, placing the mixed liquor obtained in the step S2 in an ultrasonic water bath device, carrying out ultrasonic treatment for 60min at the ultrasonic power of 600W and the frequency of 40KHz and the temperature of 50 ℃, and cooling;
s4, centrifuging, taking the ultrasonic supernatant in the step S3, and filtering to obtain an aqueous extract.
The ultrasonic processing conditions in step S3 are: the ultrasonic power is 600W, the frequency is 40KHz, and the temperature is 50 ℃;
and step S4, centrifuging for 15min under the centrifugation condition of 3000 r/min.
Example 2
The traditional Chinese medicine preparation for improving diabetic nephropathy is prepared according to the following method, and comprises the following steps:
s1, weighing raw material medicaments comprising 28 parts of astragalus membranaceus, 12 parts of eucommia ulmoides, 35 parts of corn stigma, 12 parts of coptis chinensis, 35 parts of salvia miltiorrhiza, 25 parts of polygonum aviculare, 23 parts of flatstem milkvetch seed and 28 parts of oriental wormwood in proportion, and crushing;
s2, placing the raw material medicaments crushed in the step S1 into a container, adding 50% methanol aqueous solution with the volume 6-12 times that of the raw material medicaments, heating, refluxing and cooling to obtain a mixed solution;
s3, placing the mixed liquor obtained in the step S2 in an ultrasonic water bath device, carrying out ultrasonic treatment for 60min at the ultrasonic power of 600W and the frequency of 40KHz and the temperature of 50 ℃, and cooling;
s4, centrifuging, taking the ultrasonic supernatant in the step S3, and filtering to obtain an aqueous extract.
The ultrasonic processing conditions in step S3 are: the ultrasonic power is 600W, the frequency is 40KHz, and the temperature is 50 ℃;
and step S4, centrifuging for 15min under the centrifugation condition of 3000 r/min.
Example 3
A traditional Chinese medicine composition for improving diabetic nephropathy comprises the following raw material medicines in parts by weight: 32 parts of astragalus membranaceus, 10 parts of eucommia ulmoides, 32 parts of corn stigma, 15 parts of coptis chinensis, 28 parts of salvia miltiorrhiza, 15 parts of polygonum aviculare, 18 parts of flatstem milkvetch seed and 25 parts of oriental wormwood.
Example 4
The traditional Chinese medicine preparation for improving diabetic nephropathy is prepared according to the following method, and comprises the following steps:
s1, weighing raw material medicaments comprising 25 parts of astragalus membranaceus, 18 parts of eucommia ulmoides, 28 parts of corn stigma, 5 parts of coptis chinensis, 32 parts of salvia miltiorrhiza, 18 parts of polygonum aviculare, 15 parts of flatstem milkvetch seed and 35 parts of oriental wormwood in proportion, and crushing;
s2, placing the raw material medicaments crushed in the step S1 into a container, adding 50% methanol aqueous solution with the volume 6-12 times that of the raw material medicaments, heating, refluxing and cooling to obtain a mixed solution;
s3, placing the mixed liquor obtained in the step S2 in an ultrasonic water bath device, carrying out ultrasonic treatment for 60min at the ultrasonic power of 600W and the frequency of 40KHz and the temperature of 50 ℃, and cooling;
s4, centrifuging, taking the ultrasonic supernatant in the step S3, and filtering to obtain an aqueous extract.
The ultrasonic processing conditions in step S3 are: the ultrasonic power is 600W, the frequency is 40KHz, and the temperature is 50 ℃;
and step S4, centrifuging for 15min under the centrifugation condition of 3000 r/min.
Example 5
The traditional Chinese medicine preparation for improving diabetic nephropathy is prepared according to the following method, and comprises the following steps:
s1, weighing raw material medicaments comprising 35 parts of astragalus membranaceus, 20 parts of eucommia ulmoides, 25 parts of corn stigma, 8 parts of coptis chinensis, 25 parts of salvia miltiorrhiza, 22 parts of polygonum aviculare, 25 parts of flatstem milkvetch seed and 32 parts of oriental wormwood in proportion, and crushing;
s2, placing the raw material medicaments crushed in the step S1 into a container, adding 50% methanol aqueous solution with the volume 6-12 times that of the raw material medicaments, heating, refluxing and cooling to obtain a mixed solution;
s3, placing the mixed liquor obtained in the step S2 in an ultrasonic water bath device, carrying out ultrasonic treatment for 60min at the ultrasonic power of 600W and the frequency of 40KHz and the temperature of 50 ℃, and cooling;
s4, centrifuging, taking the ultrasonic supernatant in the step S3, and filtering to obtain an aqueous extract.
The ultrasonic processing conditions in step S3 are: the ultrasonic power is 600W, the frequency is 40KHz, and the temperature is 50 ℃;
and step S4, centrifuging for 15min under the centrifugation condition of 3000 r/min.
Example 6
Based on modern pharmacological research of traditional Chinese medicines, the inventor separates out a batch of traditional Chinese medicines capable of acting on diabetic nephropathy from a traditional Chinese medicine system pharmacological database and an analysis platform (TCMSP), and screens and optimizes the medicines according to network pharmacology and traditional Chinese medicine theory to obtain a group of traditional Chinese medicine combinations for treating diabetic nephropathy. TCMSP is a traditional Chinese medicine system pharmacology database and an analysis platform which integrate pharmacokinetics, medicinal chemistry and a medicine-target protein-disease network, 499 traditional Chinese medicines in the 2010 version of the pharmacopeia of traditional Chinese medicines are collected in the database, compound information contained in each traditional Chinese medicine is obtained through document mining and database integration, target protein information of molecules of the traditional Chinese medicines is obtained through model prediction and existing experimental data, and then target protein and disease information thereof are obtained by further combining databases such as DrugBank, TTD and HIT, and finally a medicine-molecule-target-disease network for each traditional Chinese medicine is formed.
The inventor firstly obtains 499 Chinese medicines, 29384 Chinese medicine components, 3311 disease targets, 837 diseases and the mutual relations among the Chinese medicines, by downloading all data in TCMSP (http:// lsp. nwu. edu. cn/index. php), and introduces the information into Cytoscape3.6.0 network analysis software to draw a total network diagram of 'Chinese medicine-component-target-disease', as shown in figure 1. The network can be used for explaining the action characteristics of multiple components and multiple targets of the Chinese herbal compound, and on the other hand, the network can be used for searching the Chinese herbal medicine with corresponding treatment components according to diseases, thereby providing a basis for secondary development of the Chinese herbal medicine and construction of a novel compound.
On this basis, the inventor searches the disease data of the total network to obtain a module of 'diabetic nephropathy', then uses a network separation function in the Cytoscape software to separate a disease target, traditional Chinese medicine components and traditional Chinese medicine information corresponding to the diabetic nephropathy from the total network and draw a network diagram of 'traditional Chinese medicine-component-target point' of the diabetic nephropathy, as shown in figure 2, and finally uses a network analysis function to sort the traditional Chinese medicines corresponding to the diabetic nephropathy according to the quantity of pharmacodynamic components (namely, the quantity of components contained in the traditional Chinese medicines and capable of acting on the diabetic nephropathy target). The ranking results are shown in table 1 below:
TABLE 1 Chinese medicine for treating diabetic nephropathy (alternate)
According to the traditional Chinese medicine dialectical theory and epidemiological investigation and research, the diabetic nephropathy belongs to the deficiency of the origin and the excess of the origin, takes the deficiency of both the spleen and the kidney as the origin, and combines the excess syndromes of turbid toxin, water dampness, blood stasis and the like, so that the diabetes nephropathy needs to be treated by corresponding medicines for tonifying spleen and kidney, detoxifying and inducing diuresis, and activating blood and dissolving stasis. Therefore, the inventor further screens the traditional Chinese medicines obtained by the network pharmacology analysis to finally obtain the traditional Chinese medicines which contain higher quantity of effective components and have corresponding medicinal properties, including astragalus, eucommia, corn stigma, coptis chinensis and salvia miltiorrhiza. The astragalus and the eucommia are combined to strengthen the spleen and the kidney, the corn stigma and the coptis are used for detoxifying, promoting diuresis and removing turbidity, and the salvia is used for activating blood and dissolving stasis. See table 2 below:
TABLE 2 medicinal composition and dosage of hypoglycemic kidney-invigorating prescription
Example 7 Effect of Chinese medicinal composition on Kidney function in rat
Experimental animals and groups:
a common male Wistar rat is selected for experiment, after adaptive feeding for one week, fasting is carried out for 12 hours, the rat is randomly divided into a diabetic nephropathy model group and a normal control group, the model group is intraperitoneally injected with streptozotocin (0.1mol/L, prepared by sodium citrate solution) at 65mg/kg, and the control group is injected with the same amount of sodium citrate solution. Two weeks later, each group of rats was tested for blood glucose, urine glucose and urine volume. If the blood sugar value of the model rat is lower than 16.7mol/L or the urine sugar is lower than + + the blood sugar, the model rat is removed, then the model rat is continuously fed for 12 weeks, the blood sugar and the urine sugar are measured every 2 weeks, the blood creatinine, the urea nitrogen, the urine protein and the like are detected after 12 weeks, and the model rat is determined to be subjected to drug treatment after molding.
After 12 weeks the model groups were randomized into five groups of ten including the positive drug control group (IRB group): gavage with 12.5mg/kg/d irbesartan solution (IRB group); nephropathic group (ND group): performing intragastric administration with equivalent amount of normal saline; and different dosage of hypoglycemic kidney-recovering prescription treatment groups (corresponding to JTKS-L, JTKS-M, JTKS-H groups respectively): 2, 4, 8g/kg/d of the Jiangtangkang kidney prescription alcohol extract is used for gastric perfusion, the gastric perfusion lasts for 8 weeks, and a blank Control group (Control group) is used.
The positive drug irbesartan is an Angiotensin II (Angiotensin II, Ang II) receptor inhibitor, can inhibit the conversion of Ang I into Ang II, and can specifically antagonize Angiotensin converting enzyme 1 receptor (AT1), thereby inhibiting vasoconstriction and the release of aldosterone, and generating the effect of reducing blood pressure; meanwhile, the composition can relax kidney mesangial cells, improve glomerular basement membrane permeability and effectively improve the excretion and reabsorption functions of nephrons. Research shows that the medicine can effectively reduce urine protein, improve kidney function and delay the progress of kidney diseases, thus being used as a positive control of the experiment.
The detection method of the diabetic nephropathy comprises the following steps:
after 8 weeks, the values of blood sugar, creatinine and urea nitrogen of each group of rats are detected by using a biochemical kit, and the results are respectively shown in the attached figures 3 to 5. Creatinine is a product of decomposition of muscle activity and is mainly excreted through the kidney, and when a patient with kidney diseases, creatinine excretion is reduced, so that in vivo aggregation is caused, and therefore, the degree of renal function damage is clinically judged according to the amount of creatinine. Urea nitrogen is a nitrogen-containing compound in plasma other than proteins, and is filtered from the glomerulus and excreted. Since urea nitrogen increases when renal insufficiency is decompensated, it is clinically used as an index for judging the glomerular filtration function.
The results show that the blood glucose reducing and kidney recovering formula can effectively reduce the blood glucose value of a rat of a diabetic nephropathy model (figure 3), has obvious protective effect on the kidney function of the rat (figures 4 and 5), and the effect is in a dose-dependent relationship.
Claims (10)
1. A traditional Chinese medicine composition for improving diabetic nephropathy comprises the following raw material medicines in parts by weight: 25-35 parts of astragalus membranaceus, 10-20 parts of eucommia ulmoides, 25-35 parts of corn stigma, 5-15 parts of coptis chinensis and 25-35 parts of salvia miltiorrhiza.
2. The traditional Chinese medicine composition of claim 1, wherein the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 28-32 parts of astragalus membranaceus, 12-18 parts of eucommia ulmoides, 28-32 parts of corn stigma, 8-12 parts of coptis chinensis and 28-32 parts of salvia miltiorrhiza.
3. The traditional Chinese medicine composition according to claim 2, wherein the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 30 parts of astragalus membranaceus, 15 parts of eucommia ulmoides, 30 parts of corn stigma, 10 parts of coptis chinensis and 20 parts of salvia miltiorrhiza.
4. The Chinese medicinal composition according to any one of claims 1 to 3, further comprising Polygonum aviculare, Astragalus complanatus and Artemisia capillaris, wherein the Polygonum aviculare is 15-25 parts, Astragalus complanatus is 15-25 parts and Artemisia capillaris is 25-35 parts.
5. The Chinese medicinal composition according to claim 4, wherein the herba Polygoni Avicularis is 18-22 parts, the semen astragali Complanati is 18-23 parts, and the herba Artemisiae Scopariae is 28-32 parts.
6. The Chinese medicinal composition according to claim 5, wherein the herba Polygoni Avicularis comprises 20 parts, semen astragali Complanati comprises 20 parts, and herba Artemisiae Scopariae comprises 30 parts.
7. A Chinese medicinal preparation for treating diabetic nephropathy, which comprises the Chinese medicinal composition of any one of claims 1 to 6 and pharmaceutically acceptable adjuvants.
8. The traditional Chinese medicine preparation of claim 7, wherein the active ingredient of the traditional Chinese medicine preparation is an aqueous extract.
9. A method for preparing the Chinese medicinal preparation of claim 7 or 8, comprising the steps of:
s1, weighing raw material medicaments in proportion and crushing;
s2, placing the raw material medicaments crushed in the step S1 into a container, adding 50% methanol aqueous solution with the volume 6-12 times that of the raw material medicaments, heating, refluxing and cooling to obtain a mixed solution;
s3, placing the mixed liquor obtained in the step S2 in an ultrasonic water bath device, carrying out ultrasonic treatment for 60min, and cooling;
s4, centrifuging, taking the ultrasonic supernatant in the step S3, and filtering to obtain an aqueous extract.
10. The production method according to claim 9,
the ultrasonic processing conditions in step S3 are: the ultrasonic power is 600W, the frequency is 40KHz, and the temperature is 50 ℃;
and step S4, centrifuging for 15min under the centrifugation condition of 3000 r/min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910997919.5A CN110772607A (en) | 2019-10-21 | 2019-10-21 | Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910997919.5A CN110772607A (en) | 2019-10-21 | 2019-10-21 | Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110772607A true CN110772607A (en) | 2020-02-11 |
Family
ID=69386079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910997919.5A Pending CN110772607A (en) | 2019-10-21 | 2019-10-21 | Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110772607A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104971102A (en) * | 2014-04-03 | 2015-10-14 | 成都中医药大学附属医院 | Drug composition for treating diabetic nephropathy, preparation method and uses thereof |
| CN105943819A (en) * | 2016-06-22 | 2016-09-21 | 北京大学第医院 | Traditional Chinese medicine alcohol extract for treating diabetic nephropathy and preparation method and application thereof |
-
2019
- 2019-10-21 CN CN201910997919.5A patent/CN110772607A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104971102A (en) * | 2014-04-03 | 2015-10-14 | 成都中医药大学附属医院 | Drug composition for treating diabetic nephropathy, preparation method and uses thereof |
| CN105943819A (en) * | 2016-06-22 | 2016-09-21 | 北京大学第医院 | Traditional Chinese medicine alcohol extract for treating diabetic nephropathy and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘兴: "黄芪注射液合丹参注射液治疗糖尿病肾病30例", 《内蒙古中医药》 * |
| 姜兆顺等: "自拟三黄杞丹汤加减辅助治疗糖尿病肾病", 《实用医药杂志》 * |
| 安大力: "丹参与黄芪伍用降低早期糖尿病肾病患者尿微量蛋白的临床观察", 《中国现代药物应用》 * |
| 窦勇: "《糖尿病及其慢性并发症用药与食养》", 31 January 2016 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007009291A1 (en) | A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof | |
| CN101810715B (en) | New application of fructus evodiae and extracts and compounds thereof | |
| CN101371915A (en) | Method for preparing minor decoction of Bupleurum formulation | |
| JP2002154979A (en) | Medicine composition for i type allergy and method for producing the same | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN104721467B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
| CN101549010B (en) | A preparing method and application of malaytea scurfpea fruit total glycosides extract | |
| CN110772607A (en) | Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof | |
| CN1712060A (en) | Preparation of Chinese medicinal mixture for treating gynecologic menstrual disease | |
| CN1823982A (en) | Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method | |
| CN112546085A (en) | Sambucus chinensis extract for treating gout and preparation method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN108514627B (en) | Traditional Chinese medicine composition for treating chronic urticaria | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN102139002A (en) | Cortex phellodendri polysaccharide extract and preparation method and medical application thereof | |
| CN100384431C (en) | Traditional Chinese medicine compositions | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN117379505B (en) | Traditional Chinese medicine composition for treating chronic kidney disease | |
| CN101554399B (en) | Psoralea corylifolial extract with immunologic enhancement and application thereof | |
| CN105535865A (en) | Method for preparing granule medicine for treating hyperplasia of mammary glands | |
| CN101219201B (en) | Traditional Chinese medicine liquid capsule and its preparing method | |
| CN1709478A (en) | Method for preparing Chinese medicine formulation for treating gynaecological disease | |
| CN1442165A (en) | Chinese medicine for treating chronic nephritis and its preparation method | |
| CN104922489B (en) | A kind of Chinese medicine composition for treating chronic nephritis and preparation method thereof | |
| CN100361662C (en) | Preparation method of traditional Chinese medicine compositions formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200211 |
|
| RJ01 | Rejection of invention patent application after publication |